FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Enanta Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Enanta Pharmaceuticals, Inc. (ENTA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisENTA
ENTA
Enanta Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ENTA
Home🔹Stocks🔹Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTA•NASDAQ

Enanta Pharmaceuticals, Inc.

ENTA•NASDAQ
Market cap
$366.68M
Sentiment

Your view on ENTA

Mkt Cap
$366.68M
Sentiment
Your view
ENTA
Enanta Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ENTA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Enanta Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jay R. Luly
Headquarters
500 Arsenal Street, Watertown, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jay R. Luly
Headquarters
500 Arsenal Street, Watertown, MA, US
Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News